<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01//EN" "http://www.w3.org/TR/html4/strict.dtd">
<html>
<head>
    <meta http-equiv="Content-Type" content="text/html; charset=iso-8859-1">
    <title>UCSC Ebola Portal</title>
    <link rel="stylesheet" href="../style/HGStyle.css" type="text/css">
    <link rel="stylesheet" href="../style/encodeProject.css" type="text/css">
    <style>
        /* using tables for layout */
        table {
            border-style: none
        }
        td {
            border-style: none;
            vertical-align: top;
        }

        /* override visited img links in HGStyle */
        .screenshot {
            display: block;
            width: 100%;
            margin: 15px 0 !important;
        }
        .screenshot:hover {
            outline: 1px solid ActiveBorder;
        }

        .header {
            color: #00457c;
            font-size: 25px;
            margin-top: 25px;
            margin-bottom: 15px;
        }
        .header span {
            vertical-align: middle;
            width: 30%;
        }
        .subHeader {
            font-size: 15px;
            background-color: #efefef;
        }

        .bar {
            height: auto;
            padding-bottom: 4px;
        }
        .wrapper {
            border: none;
        }
    </style>
</head>

<body style="margin:0;">
    <!--#include virtual="../inc/ebola.topbar.html"-->
    <div class="header">
        <span class="txt">&nbsp; UCSC Ebola Genome Portal</span>
        <span class="subHeader">Resources for the 2014 West Africa outbreak</span> 
    </div>
    <div style="margin:8px; margin-right:16px;">
        <table>
            <tr>
            <td colspan="3">
            <div style="margin-top: 0; margin-left: 10px;" class="wrapper">
                <div class="bar"><h4 class="title">About</h4></div>
                <div class="content">
                <p>
                The 2014 Ebola epidemic in West Africa has stirred international response and
                renewed efforts to develop effective preventative and treatment options.
                In response to a request for help from vaccine researchers, we have fast-tracked
                the
                <a target="_blank" href="../cgi-bin/hgTracks?db=eboVir2">UCSC Ebola Genome Browser</a>
                built with viral sequences from previous outbreaks as
                well as the 2014 outbreak.  
		This site also provides related tools and 
                information that can be used to further the understanding of Ebola.</p>
                </div><!--end content-->
            
            </td>
            </tr>
            <!-- screenshot launchers 2x2 matrix -->
                <tr>
                    <!-- Browser image linking to browser CGI -->
                    <td width="44%">
                    <div style="margin-top:0; margin-left:10px; margin-right:10px" class="wrapper">
                    <div class="bar"><h4 class="title">Explore the Ebola genome with the UCSC 
			Genome Browser</h4></div>
                        <div class="content">
                            <a href="../cgi-bin/hgTracks?db=eboVir2"><img class="screenshot" src="../images/ebolaBrowser.png"></a>
                        </div>
                    </div>
                    </td>

                    <!-- Incidence graph linked to CDC site -->
                    <td width="41%" >
                    <div style="margin-top:0; margin-right: 10px;" class="wrapper">
                        <div class="bar"><h4 class="title">Learn about the 2014 outbreak</h4></div>
                            <a href="http://www.cdc.gov/vhf/ebola/"><img class="screenshot"  src="../images/Graph_Diseased_Ebola_2014.png"></a>
                    </div>
                    </td>

                    <!-- Electron micrograph of virus linked to Wikipeda page -->
                    <td width="15%" >
                    <div style="margin-top:0;" class="wrapper">
                        <div class="bar"><h4 class="title">Read about Ebola</h4></div>
                            <a href="http://en.wikipedia.org/wiki/Ebola_virus" target="_blank"><img class="screenshot" src="../images/Zaire_ebolavirus_vertical.jpg"></a>
                    </div>
                    </td>
                </tr>

<!-- Publications block -->
            <tr>
            <td colspan="3">
            <div style="margin-top: 15px; margin-left: 10px;" class="wrapper">
            <div class="bar"><h4 class="title">Related Publications</h4></div>
            <div class="content">
		<p>
  		PLOS Ebola Flipboard:  
        	<a href="https://flipboard.com/section/plos-ebola-collection-bRVgYj" 
		target="_blank">PLOS Ebola Collection</a> (all currently published articles, freely 
		available)
		</p>
		<p>
    		Science Magazine collection: 
        	<a href="http://www.sciencemag.org/site/extra/ebola/" target="_blank">Science 
		Magazine Special Collection: Ebola Virus</a> (freely available research and news 
		articles)
		</p>
		<p>
                99 viral genome sequences from Sierra Leone:
		<a href="http://www.ncbi.nlm.nih.gov/pubmed/25214632"
                target="_blank">Genomic surveillance elucidates Ebola virus origin and transmission 
		during the 2014 outbreak</a>
		[<a href="http://www.sciencemag.org/content/345/6202/1369.full.pdf"
                target="_blank">PDF</a>]
		</p>
            </div>
            </div><!--end content-->
            </div><!--end wrapper-->
            </td>
            </tr>

<!-- Ebola Biology block -->
            <tr>
            <td colspan="3">
            <div style="margin-top: 0; margin-left: 10px;" class="wrapper">

            <div class="bar"><h4 class="title">Ebola Biology</h4></div>
            <div class="content">
		<p>
                Ebola virus is the causative agent of Ebola hemorrhagic fever (EHF), 
                a disease affecting humans and other primates. The incubation period 
                for EHF is 2-21 days and typical early symptoms include fever, chills, 
                malaise, and myalgia, followed by the onset of symptoms indicative of 
                multi-organ stress and subsequent failure. The disease is also characterized 
                by high death rates (as high as 90%) and worse yet, is highly contagious, 
                spreading through direct contact with infected body fluids or skin/mucus membrane 
		contact.
                This perfect storm of conditions make the possibility of a large-scale epidemic
                a very real concern.
		</p>
		<p>
                Ebola virus and the related Marburg virus are members of the family 
                Filoviridae, so named for their filamentous shape. Like other Filoviruses, 
                Ebola is an enveloped, non-segmented, negative-stranded RNA virus. Ebola virus 
                particles have at their core a viral nucleocapsid composed of a helical single 
                stranded RNA genome wrapped around viral proteins NP, VP35, VP30, and L. The 
                nucleocapsid is surrounded by an outer viral envelope studded with viral 
                glycoprotein (GP) spikes, and viral proteins VP40 and VP24 sit between the 
                nucleocapsid and the envelope.
		</p>
		<p>
                The viral life cycle begins with host cell entry through a poorly understood 
		mechanism. Once inside 
                the viral RNA-dependent RNA polymerase (L) binds the 19 kb genome as a complex with 
                other factors and transcribes the negative strand genome into a positive strand 
                mRNA to be translated by the host cell's machinery. The seven genes are ordered in 
		the genome as follows: 3-leader-NP-VP35-VP40-GP/sGP-VP30-VP24-L-trailer-5'. Once the
		concentration of nucleocapsid protein (NP) reaches a sufficient level, the RNA 
		polymerase switches 
                modes to genome replication, producing full-length positive strand genomes to be 
                transcribed into negative orientation. These genomes self assemble with 
                other virus proteins and bud from the host cell, sheathed in host 
                cell membrane, thus completing the cycle.
		</p>
            </div><!--end content-->
            </div><!--end wrapper-->
            </td>
            </tr>

<!--Vaccines panel -->
<a name="vaccines">
            <tr>
            <td colspan="3">
            <div style="margin-top: 0; margin-left: 10px;" class="wrapper">
                <div class="bar"><h4 class="title">Vaccine Development</h4></div>
            <div class="content">
		<p>
                In September 2014 Phase 1 clinical trials of the GlaxoSmithKline ChAd3/EBOV vaccine
                began at the US National Institutes of Health and UK Oxford, and
                a second vaccine (VSV/EBOV, produced by Newlink Genetics), 
                was approved for trial by the US FDA.
                If the vaccines are found to be safe, some doses could be available 
                for use in healthcare workers in November.
                <ul>
                <li>
                <a href="http://www.niaid.nih.gov/news/QA/Pages/EbolaVaxQA.aspx" target="_blank">Phase 1 Clinical Trials of NIAID/GSK Investigational Ebola Vaccine</a>
                </li>
                <li>
                <a href="http://www.ox.ac.uk/news/2014-08-28-oxford-lead-ebola-vaccine-trial"> Oxford to lead Ebola vaccine trial</a>
                </li>
                <li>
                <a href="http://investors.linkp.com/releasedetail.cfm?ReleaseID=869082">FDA Gives NewLink Genetics Approval to Proceed to Phase 1 Clinical Studies of Their Ebola Vaccine</a>
                </li>
                </ul>
                Other vaccines have been tested in non-human primates with good results.
                Ebola mutates slower than many viruses (e.g. HIV) and is considered a
                good vaccine target.
                We have collected some review articles and research reports pertaining to 
                Ebola vaccine development here:
                <a href="https://docs.google.com/spreadsheets/d/1CeDZQ7MztauDl1c11eAPx6iIUUEIFfQUYBxNHUQ5PhM/pubhtml" target="_blank">Ebola Vaccine Development: Scientific References</a>
                </p>
                A vaccine will do much to slow the spread of this epidemic.  
                After preliminary safety trials the question becomes how fast production be scaled,
                which is contingent on funding.
                At this time, GlaxoSmithKline has committed to the production of 10,000 vaccine doses 
                by years end.
                With the US committing significant federal funds to the fight against Ebola,
                we can hope that vaccines will be available in quantity. 
                From Marie-Paule Kieny, assistant director-general of WHO, who spoke at a press
                conference in Geneva in early September; "There is a tide in the affairs of men,
                and that tide is now."
		</p>
            </div><!--end content-->
            </div><!--end wrapper-->
            </td>
            </tr>

<a name="antibodies">

<!--Antibodies panel -->
            <tr>
            <td colspan="3">
            <div style="margin-top: 0; margin-left: 10px;" class="wrapper">
            <div class="bar"><h4 class="title">Antibody Resources</h4></div>
            <div class="content">
		<p>

		This section contains links to papers and other resources related to antibody use 
		in the treatment and vaccine development for Ebola Virus Disease.
		</p>
		<p>
                Neutralizing antibodies for Kikwit strain (1999):
	   	<a href="http://www.ncbi.nlm.nih.gov/pubmed/10364354"
                target="_blank"> Ebola virus can be effectively neutralized by antibody produced in 
		natural human infection</a>
                [<a href="http://jvi.asm.org/content/73/7/6024.full.pdf" target="_blank">PDF</a>]
		</p>
		<p>
                Humanized mAbs (ZMapp) expressed in tobacconists (2014):
		<a href="http://www.ncbi.nlm.nih.gov/pubmed/25171469"
                target="_blank">Reversion of advanced Ebola virus disease in nonhuman primates with 
		ZMapp</a>
                [<a href="http://www.nature.com/nature/journal/vnfv/ncurrent/pdf/nature13777.pdf"
                target="_blank">PDF</a>]
		</p>
                mAbs (MB-003) cocktail (2012): 
                <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3497800" target="_blank">Delayed treatment of Ebola virus infection with plant-derived monoclonal antibodies provides protection in rhesus macaques</a>
                <p>
                <p>
                EBOV IgG+ sera from asymptomatic individuals and symptomatic Gabonese survivors 
		(2014):
		<a href="http://www.ncbi.nlm.nih.gov/pubmed/24914933" 
		target="_blank">Identification of continuous human B-cell epitopes in the VP35, 
		VP40, nucleoprotein and glycoprotein of Ebola virus</a>
                [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4051576/pdf/pone.0096360.pdf" 
                target="_blank">PDF</a>]
                </p>
                <p>
                Mouse mAb binding sites mapped to seven antigenic regions, two highly conserved,
		across all known Ebolavirus species (2013):
                <a href="http://www.ncbi.nlm.nih.gov/pubmed/23702199" 
		target="_blank">Mapping of conserved and species-specific antibody epitopes on the 
		Ebola virus nucleoprotein</a>
                [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3787873/pdf/nihms516287.pdf"
                target="_blank">PDF</a>]
                </p> 
                <p>
                Literature links from 
                <a href="http://help.iedb.org/entries/51011785-Ebola-virus-related-immune-epitope-data-curated-in-the-IEDB"
		target="_blank">Reported functional EBOV-related B cell epitopes</a> (Table 2) on
		the <a href="http://www.iedb.org/" 
		target="_blank">Immune Epitope Database and Analysis Resource</a> (IEDB) website: 
                </p>
                <ul>
                <li>
                (2012) <a href="http://www.mdpi.com/1999-4915/4/4/447" 
		target="_blank">Structural basis for differential neutralization of ebolaviruses</a>
                </li>
                <li>
                (2011) <a href="http://linkinghub.elsevier.com/retrieve/pii/S1521-6616(11)00242-7"
		target="_blank">Characterization of Zaire ebolavirus glycoprotein-specific 
		monoclonal antibodies</a>
                </li>
                <li>
                (2008) <a href="http://www.ncbi.nlm.nih.gov/pubmed/18005986" 
		target="_blank">Complex of a protective antibody with its Ebola virus GP peptide 
		epitope: unusual features of a V lambda x light chain</a>
                </li>
                <li>
                (2008) <a href="http://dx.doi.org/10.1038/nature07082" 
		target="_blank">Structure of the Ebola virus glycoprotein bound to an antibody from 
		a human survivor</a>
                </li>
                <li>
                (2003) <a href="http://jvi.asm.org/cgi/pmidlookup?view=long&amp;pmid=12502822" 
		target="_blank">Identification of protective epitopes on ebola virus glycoprotein 
		at the single amino acid level by using recombinant vesicular stomatitis viruses</a>
                </li>
                <li>
                (2000) <a href="http://www.sciencemag.org/cgi/pmidlookup?view=long&amp;pmid=10698744" 
		target="_blank">Epitopes involved in antibody-mediated protection from Ebola 
		virus</a>
                </li>
                </ul>
            </div>
            </div><!--end content-->
            </div><!--end wrapper-->
            </td>
            </tr>


<!-- PR Links block -->
            <tr>
            <td colspan="3">
            <div style="margin-top: 0; margin-left: 10px;" class="wrapper">

            <div class="bar"><h4 class="title">General Interest Links</h4></div>
            <div class="content">
		<p>
                <a href="http://www.youtube.com/watch?v=qTcfnTISMDk"
		target="_blank">NOVA: Ebola, The Plague Fighters</a> (1995)
		</p>
		<p>
		<a href= "https://www.youtube.com/watch?v=jTF7i6OBGQk"
		target="_blank">Fighting to Contain Sierra Leone's Ebola Epidemic</a> (2014)
		</p>
                <p>
		<a href= "https://www.youtube.com/watch?v=1_WOR22-SnY" 
		target="_blank">A popular song in Africa about Ebola</a> (note: graphic
		visual content)
                </p>
            </div>
            </div><!--end content-->
            </div><!--end wrapper-->
            </td>
            </tr>
            </table>
</body>
</html>
